Table 1.
Characteristics of the included clinical trials
| Author | Study duration | N | Study groups (dutasteride dose) | Administration route | Time lapse between doses | Age, years | Mean change in hair count in 1 cm | Mean change in HGSS | Self-assessed improvement, % |
|---|---|---|---|---|---|---|---|---|---|
| Harcha et al. [17] | 24 weeks | 185 | 0.02-mg DU | Oral | Daily | 38.5 (7.72)a | 3.37 | 8.5 | − |
| 188 | 0.1-mg DU | 38.7 (7.44)a | 12.45 | 11.4 | − | ||||
| 184 | 0.5-mg DU | 38.6 (7.66)a | 17.7 | 12 | − | ||||
| 181 | Placebo | 38.7 (8.43)a | −0.96 | 9.1 | − | ||||
| Tsai et al. [21] | 48 weeks | 58 | 0.5-mg DU | Oral | Daily | 39 (23−50) (general)b | − | 3.2 | − |
| 59 | Placebo | − | −0.1 | − | |||||
| Stough [20] | 12 months | 17 | 0.5-mg DU | Oral | Daily | − | 16.5 | − | Slightly improved |
| 17 | Placebo | − | −3.8 | − | No improvement | ||||
| Eun et al. [23] | 24 weeks | 73 | 0.5-mg DU | Oral | Daily | 37.8 (7.1)a | 12.2 | − | 71.2+ |
| 75 | Placebo | 38.4 (6.6)a | 4.7 | − | 36+ | ||||
| Olsen et al. [16] | 24 weeks | 71 | 0.05-mg DU | Oral | Daily | 35.5 (5.83)a | 5.45 | − | 58* |
| 72 | 0.1-mg DU | 36.4 (6.48)a | 15.51 | − | 57* | ||||
| 68 | 0.5-mg DU | 36.1 (6.31)a | 18.69 | − | 56* | ||||
| 71 | 2.5-mg DU | 35.8 (5.89)a | 21.66 | − | 72* | ||||
| 64 | Placebo | 35.8 (6.15)a | −6.38 | − | 42* | ||||
| Moftah et al. [19] | 18 weeks | 86 | 0.5-mg DU | Intralesional | Weekly (12 weeks) | 34.1 (6.6)a | − | − | 66.6+ |
| 40 | Saline solution 0.9% | 34.8 (7.2)a | − | − | 28.7+ | ||||
| Sobhy et al. [22] | 20 weeks | 30 | 0.005% pure DU | Intralesional | Weekly (1st month) | 29.5c | 60* | ||
| 30 | 0.5-mg DU solution | Biweekly (2 nd month) | 30c | − | − | 90* | |||
| 30 | Saline solution 0.9% | Monthly (3rd–5th month) | 28.5c | − | − | 40* | |||
| Abdallah [18] | 12 weeks | 14 | 0.05% DU | Intralesional | Weekly (1st month) | 30.2 (8.7)a | 7.73 | − | 92.9+ |
| 14 | Saline solution 0.9% | Biweekly (2 nd month) | 31.3 (7.6)a | −0.17 | − | 7.1+ | |||
| Monthly (3rd month) | |||||||||
In the study by Tsai et al., subjects who received dutasteride did so for 48 weeks, subjects who received placebo did so for 24 weeks, and results were gathered at the week 24 endpoints. In the study by Moftah et al., self-assessed improvement was obtained as an average for all 4 self-assessed categories (hair density, hair thickness, hair falling, and changes in color and brightness). All groups from each study followed the same time lapse between doses as specified in each box. On self-assessed improvement, values marked with “
” refer to % treatment satisfaction and values marked with “+” refer to perceived improvement %. DU, dutasteride; HGSS, Hair Growth Satisfaction Scale.
Mean, SD.
Mean, range.
Median range.